U
IRWD icon

UBS’s Ironwood Pharmaceuticals IRWD Stock Holding History

UBS’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-262,680
Closed -$3.37M – 10539
2014
Q2 		$3.37M Buy
+262,680
New +$2.86M ﹤0.01% 2335

Other funds holding IRWD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

UBS's IRWD Position: Q3 2014 in Review

UBS reduced its Ironwood Pharmaceuticals (IRWD) stake by 98% in Q3 2014, selling an estimated $939K and leaving 2,062 shares worth $22K. The position accounts for ﹤0.01% of the portfolio, ranked #7882.

UBS first reported a position in IRWD in Q4 2013 and has held it in 4 quarters since. The position peaked at $1.08M in Q2 2014. 140 funds tracked by Wall St. Rank hold IRWD as of Q3 2014.

  • UBS held 2,062 shares of Ironwood Pharmaceuticals worth $22K as of Q3 2014.
  • UBS sold 82,053 Ironwood Pharmaceuticals shares in Q3 2014, an estimated $939K.
  • Ironwood Pharmaceuticals made up ﹤0.01% of UBS's portfolio in Q3 2014, its #7882 holding.
  • UBS first reported a position in Ironwood Pharmaceuticals in Q4 2013 and has held it in 4 quarters since.
  • UBS's Ironwood Pharmaceuticals position peaked at $1.08M in Q2 2014.
  • 140 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.